MeSH D050177 - overweight
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
No data
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novo Nordisk | Liraglutide | Saxenda | 2015-03-23 | |||
| Semaglutide | Wegovy | 2022-01-06 | ||||
| Orexigen Therapeutics | Bupropion, Naltrexone | Mysimba | 2015-03-26 |
Clinical Trials
Historical Success Rate
Phase 1
50%7/14
Phase 2
36%14/39
Phase 3
50%14/28
Approved: 4Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use